Abstract
Purpose: Osteoarthritis (OA) is characterized by progressive, irreversible erosion of articular cartilage that may be evoked during progressive age and after traumatic insult. This study aims to assess the attributes of HU308- a selective cannabinoid receptor type 2 (CB2) agonist, to serve as a potential Disease modified OA drug (DMOAD). We further attempted to elucidate the mechanism, by which HU308 may contribute to preserving joint cartilage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
